Skip to main content
SpringerLink
Log in

Quality of Life Assessments in Clinical Trials of Angina Pectoris

  • Chapter
Drug Evaluation in Angina Pectoris

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 158))

Abstract

Available data indicate that the clinical efficacy outcomes used in angina pectoris trials only bear a moderate relationship to how patients feel and function in daily life. Therefore, quality of life assessments may provide important supplementary information. Up until now most quality of life studies in angina pectoris have focused on newer treatment options with a clear marketing perspective. There are, however, several methodological issues that need consideration when studies are planned. One should be aware of the quite pronounced placebo effects and, concerning organic nitrate esters, the comparatively high incidence of headaches, at least in the early treatment phase.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Wenger NK. Assessment of quality of life: A medical imperative. Cardiovasc Drugs Ther 1988;1:553–558.

    Article  PubMed  CAS  Google Scholar 

  2. Kaplan RM. Health-related quality of life in cardiovascular disease. J Consult Clin Psychol 1988;56:382–392.

    Article  PubMed  CAS  Google Scholar 

  3. Revicki DA. Quality of life research and the health care industry. J Res Pharma Econ 1990;2:41–53.

    Google Scholar 

  4. Coons SJ, Kaplan RM. Assessing health-related quality of life: Application to drug therapy. Clin Therap 1992;14;850–858.

    CAS  Google Scholar 

  5. Patrick DL. Health-related quality of life in pharmaceutical evaluation. Forging progress and avoiding pitfalls. PharmacoEconomics 1992;1:76–78.

    Article  PubMed  CAS  Google Scholar 

  6. O’Brien B, Rushby J. Outcome assessment in cardiovascular cost-benefit studies. Am Heart J 1990;119:740–747; discussion 747–748.

    Article  PubMed  Google Scholar 

  7. Drummond M, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992;6:495–501.

    PubMed  CAS  Google Scholar 

  8. Revicki DA, Rothman M, Luce B. Health-related quality of life assessments and the pharmaceutical industry. PharmacoEconomics 1992;1:394–408.

    Article  PubMed  CAS  Google Scholar 

  9. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985;69:1155–1159.

    PubMed  CAS  Google Scholar 

  10. Henry D. Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992;1:54–67.

    Article  PubMed  CAS  Google Scholar 

  11. Henderson-James D, Spilker B. An industry perspective. In: B Spilker, ed. Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990:183–192.

    Google Scholar 

  12. Morris LA. A marketing perspective. In: B Spilker, ed. Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990;171–182.

    Google Scholar 

  13. Taylor SH. Drug therapy and quality of life in angina pectoris. Am Heart J 1987;114:234–240.

    Article  PubMed  CAS  Google Scholar 

  14. Mayou R. The patient with angina: Symptoms and disability. Postgrad Med J 1973;49:250–254.

    Article  PubMed  CAS  Google Scholar 

  15. Dongier M. Psychosomatic aspects in myocardial infarction in comparison with angina pectoris. Psychother Psychosom 1974;23:123–131.

    Article  PubMed  CAS  Google Scholar 

  16. Smith TW, Follick MJ, Korr KS. Anger, neuro-ticism, type A behaviour and the experience of angina. Br J Med Psychol 1984;57:249–252.

    Article  PubMed  Google Scholar 

  17. Ostfeld AM, Lebovits BZ, Shekelle RB, Paul O. A prospective study of the relationship between personality and coronary heart disease. J Chronic Dis 1964;17:265–276.

    Article  Google Scholar 

  18. Vázquez-Barquero JL, Padierna-Acero JA, Ochoteco A, Diez-Manrique JF. Mental illness and ischemic heart disease: Analysis of psychiatric morbidity. Gen Hosp Psychiatr 1985;7:15–20.

    Article  Google Scholar 

  19. Rosengren A, Hagman M, Pennert K, Wilhelmsen L. Clinical course and symptomatology of angina pectoris in a population study. Acta Med Scand 1986;220:117–126.

    Article  PubMed  CAS  Google Scholar 

  20. Walter PJ. Return to work after coronary artery bypass surgery. Eur Heart J 1988;9(Suppl L):58–66.

    Article  PubMed  Google Scholar 

  21. Wiklund I, Herlitz J, Hjalmarson Å. Quality of life five years after myocardial infarction. Eur Heart J 1989;10:464–472.

    PubMed  CAS  Google Scholar 

  22. Uusitalo A, Arstila M, Bae EA, Harkonen R, Keyrilainen O, Rytkonen U, Schjelderup-Mathiesen PM, Wendelin H. Metoprolol, nifedipine, and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733–737.

    Article  PubMed  CAS  Google Scholar 

  23. Nyberg G, Carlens P, Lindstrom E, Lundman T, Nordlander R, Rehnqvist N, Ulvenstam G, Åberg A, Astrom H. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study. Eur Heart J 1986;7:835–842.

    PubMed  CAS  Google Scholar 

  24. Ghio S, Specchia G. Clinical evaluation of calcium-antagonist drugs. J Cardiovasc Pharmacol 1992;20(Suppl 7):S71–S74.

    Article  PubMed  Google Scholar 

  25. Hammershoy O. A Nordic multicentre dose-response study of metoprolol in angina pectoris patients. Curr Ther Res 1982;31:1026–1034.

    Google Scholar 

  26. Mehta J, Conti R, Pepine CJ. Long-term oral verapamil therapy in patients with rest angina. Am Heart J 1983;106:1133–1137.

    Article  PubMed  CAS  Google Scholar 

  27. Ueberbacher HJ, Patyna WD, Krepp P, Puespoek J, Neuhaus R, Hilbich K, Bulitta M, Rittinghausen R. Randomisierter, doppel-blinder Vergleich von Isosorbid-5-Mononitrat und retardiertem Nifedipin bei Patienten mit stabiler Belastungsangina. Multicenter Studien-Gruppe. Schweiz Med Wochenschr 1991;121:1836–1840.

    PubMed  CAS  Google Scholar 

  28. Sterndorff B. Efficacy and acceptability of sustained release glyceryl trinitrate (Sustac) tablets at high dosage in patients with severe angina pectoris. Br J Clin Pract 1985;39:235–237.

    PubMed  CAS  Google Scholar 

  29. Wheatley D. A comparison of diltiazem and atenolol in angina. Postgrad Med J 1985;61:785–789.

    Article  PubMed  CAS  Google Scholar 

  30. Tremblay G. High-dose isosorbide dinitrate in management of angina pectoris. Am Heart J 1985;110:280–284.

    Article  PubMed  CAS  Google Scholar 

  31. Jachuck SJ, Bnerley H, Jachuck S, Willcox PM. The effect of hypertensive drugs on the quality of life. J R Coll Gen Pract 1982;32:103–105.

    PubMed  CAS  Google Scholar 

  32. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988;57:109–112.

    Article  PubMed  CAS  Google Scholar 

  33. Rector TS, Francis GS, Cohn JN. Patients’ self-assessment of their congestive heart failure. Part 1. Patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Failure 1987,3:192–196.

    Google Scholar 

  34. Wiklund I, Comerford B, Dimenaes E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol 1991;14:204–208.

    Article  PubMed  CAS  Google Scholar 

  35. Permanyer-Miralda G, Alonso J, Anto JM, Alijarde-Guimera M, Soler-Soler J. Comparison of perceived health status and conventional functional evaluation in stable patients with coronary artery disease. J Clin Epidemiol 1991;44:779–786.

    Article  PubMed  CAS  Google Scholar 

  36. Knuuti J, Wahl M, Wiklund I, Smith P, Alhainen L, Harkonen R, Puska P, Tzivoni D. Intermittent and continous nitrate therapy: Acute and long term effects on myocardial ischemia in patients with stable angina pectoris during daily life. Am J Cardiol 1992;69:1525–1532.

    Article  Google Scholar 

  37. Fallowfield LJ, Baum M, Maguire GP. Do psychological studies upset patients? J R Soc Med 1987;80:59.

    PubMed  CAS  Google Scholar 

  38. Wiklund I, Dimenaes E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Controlled Clin Trials 1990;11:169–179.

    Article  PubMed  CAS  Google Scholar 

  39. MacKeigan LD, Pathak DS. Overview of health-related quality of life measures. Am J Hosp Pharm 1992;49:2236–2245.

    PubMed  CAS  Google Scholar 

  40. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR. Quality of life assessment: Can we keep it simple? J R Statis Soc, Ser A, 1992;155:353–393.

    Article  Google Scholar 

  41. Fitzpatnck R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 1992;305:1074–1077.

    Article  Google Scholar 

  42. Fletcher AE. Measurement of quality of life in clinical trials of therapy. Recent Results Cancer Res 1988;111:216–230.

    Article  PubMed  CAS  Google Scholar 

  43. Aaronson NK. Quality of life assessments in clinical trials: Methodological issues. Controlled Clin Trials 1989;10:195S–208S.

    Article  PubMed  CAS  Google Scholar 

  44. Aaronson NK. Assessing the quality of life in patients in cancer clinical trials: Common problems and common sense solutions. Eur J Cancer 1992;28A:1304–1307.

    Article  PubMed  CAS  Google Scholar 

  45. Guyatt G, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL. Measuring quality of life in clinical trials: A taxonomy and review. Can Med Assoc J 1989;140:1441–1448.

    CAS  Google Scholar 

  46. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27:217–232.

    Article  Google Scholar 

  47. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A, Mowat A. Importance of sensitivity to change as a criterion for selecting health status measures. Qual Health Care 1992;1:89–93.

    Article  PubMed  CAS  Google Scholar 

  48. Mayou R. Quality of life in cardiovascular disease. Psychother Psychosom 1990;54:99–109.

    Article  PubMed  CAS  Google Scholar 

  49. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657–1664.

    Article  PubMed  CAS  Google Scholar 

  50. Wiklund I, Holst J, Karlberg J, Mattson L-Å, Samsioe G, Sandin K, von Schoulz B. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211–224.

    Article  PubMed  CAS  Google Scholar 

  51. Hjemdahl P, Wiklund I. Quality of life on antihypertensive drug therapy—scientific end-point or marketing exercise? J Hypertens 1992;10:1437–1446.

    Article  PubMed  CAS  Google Scholar 

  52. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985;38:27–36.

    Article  PubMed  CAS  Google Scholar 

  53. Anon. Quality of life ad claims should not be based on open-label “seeding” studies; FDA has continuing “concerns” about quality of life claims in general. FDC Reports 1991;January 21:15–16.

    Google Scholar 

  54. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care II: Design analysis and interpretation. Br Med J 1992;305:1145–1148.

    Article  CAS  Google Scholar 

  55. Wilson A, Wiklund I, Lahti T, Wahl M. A summary index for the assessment of quality of life in angina pectoris. J Clin Epidemiol 1991;44:981–988.

    Article  PubMed  CAS  Google Scholar 

  56. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101–107.

    Article  PubMed  CAS  Google Scholar 

  57. Rector TS, Kubo SH, Cohn JN. Patients’ self assessment of their congestive heart failure: Content, reliability and validity of a new measure—the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198–209.

    Google Scholar 

  58. Bulpitt CJ, Fletcher AE. Measurement of quality of life in angina. J Hypertens 1987;5(Suppl):S41–S45.

    Article  CAS  Google Scholar 

  59. Hartman KE, Nordstrom LA, Gobel FL. The effect of placebo therapy on exercise response and nitroglycerin consumption in patients with angina pectoris. Circulation 1974;49(Suppl 3):115.

    Google Scholar 

  60. Boissel JP, Philippon AM, Gauthier E, Schbath J, Destors JM. Time course of long-term placebo therapy effects in angina pectoris. Eur Heart J 1986;7:1030–1036.

    PubMed  CAS  Google Scholar 

  61. Roethlisberger FJ, Dickson WJ. Management and the Worker. Cambridge, MA: Harvard University Press, 1947.

    Google Scholar 

  62. Folli G, Radice M, Beltrami A, Potenza S, Mariotti G. Placebo effect in the treatment of angina pectoris. Acta Cardiol 1978;33:231–239.

    PubMed  CAS  Google Scholar 

  63. Thadani U, Hamilton SF, Olson E, Anderson JL, Prasad R, Voyles W, Doyle R, Kirsten E, Teague SM. Duration of effects and tolerance of slow-release isosorbide-5-monomtrate for angina pectoris. Am J Cardiol 1987;59:756–762.

    Article  PubMed  CAS  Google Scholar 

  64. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol 1991;41:5–9.

    Article  PubMed  CAS  Google Scholar 

  65. Nissinen A, Wiklund I, Lathi T, Wilson A, Wahl M, Puska P. Anti-anginal therapy and quality of life. A comparison of transdermal nitroglycerin and long-acting oral nitrates. J Clin Epidemiol 1991;44:989–997.

    Article  PubMed  CAS  Google Scholar 

  66. Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: A randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 1988;2:4–8.

    Article  PubMed  CAS  Google Scholar 

  67. Wiklund I, Karlsson BW, Johansson S, Bengtsson A, Herlitz J. Well-being differs in men and women after myocardial infarction. Eur Heart J, in press.

    Google Scholar 

  68. Tibblin G, Bengtsson C, Furunes B, Lapidus L. Symptoms by age and sex. The population studies of men and women in Gothenburg, Sweden. Scand J Prim Health Care 1990;8:9–18.

    Article  CAS  Google Scholar 

  69. Coronary Artery Surgery Study (CASS). A randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation 1983;68:951–960.

    Article  Google Scholar 

  70. Wortman PM, Yeaton WH. Cumulating quality of life results in controlled trials of coronary artery bypass graft surgery. Controlled Clin Trials 1985;6:289–305.

    Article  PubMed  CAS  Google Scholar 

  71. Langeluddecke P, Fulcher G, Baird D, Hughes C, Tennant C. A prospective evaluation of the psychosocial effects of coronary artery bypass surgery. J Psychosom Res 1989;33:37–46.

    Article  PubMed  CAS  Google Scholar 

  72. Follick MJ, Gorkin L, Smith TW, Capone RJ, Visco J, Stablein D. Quality of life post-myocardial infarction: Effects of a transtelephonic coronary intervention system. Health Psychol 1988;7:169–182.

    Article  PubMed  CAS  Google Scholar 

  73. McKenna KT, McEniery PT, Maas F, Aroney CN, Bett JHN, Cameron J, Garrahy P, Holt G, Hossack KF, Murphy AL. Clinical results and quality of life after percutaneous transluminal coronary angioplasty: A preliminary report. Cathete Cardiovasc Diagn 1992;27:89–94.

    Article  CAS  Google Scholar 

  74. Prichard BN. Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs 1974;7:55–84.

    Article  PubMed  CAS  Google Scholar 

  75. Lee G, Mason DT, Amsterdam EA, Miller RR, DeMaria AN. Antianginal efficacy of oral therapy with isosorbide dinitrate capsules. Prolonged benefit shown by exercise testing in patients with ischemic heart disease. Chest 1978;73:327–332.

    Article  PubMed  CAS  Google Scholar 

  76. Fletcher A, Bulpitt CJ. Quality of life on angina therapy. Lancet 1988;2:959.

    Article  PubMed  CAS  Google Scholar 

  77. Jonsson B, Bjork S, Hofvendahl S, Levin J-E. Quality of life in angina pectoris: A Swedish randomized crossover comparison between Transiderm Nitro and long-acting oral nitrates. In: W van Eimeren, B Horisberger, eds. Socioeconomic Evaluation of Drug Therapy. Springer Verlag, 1988:166–180.

    Google Scholar 

  78. Brady EM, Gold OG, Rosenbach HJ. Antianginal efficacy of transdermal nitroglycerin and oral nitrates the ACTION study. Z Klin Med 1992;47:94–98.

    Google Scholar 

  79. Jern S. The effects of epanolol on quality of life. Drugs 1989;38(Suppl 2):71–74.

    Article  PubMed  Google Scholar 

  80. Blake P, Berry SC, Readman A, Ratcliffe M, Godley M. A comparison of epanolol and nifedipine in stable angina patients: Results of a multicenter trial. Cardiology 1991;79:249–255.

    Article  PubMed  CAS  Google Scholar 

  81. Boberg J, Larsen FF, Pehrsson SK. The effects of beta-blockade with epanolol and without atenolol intrinsic sympathomimetic activity in stable angina pectoris. Clin Cardiol 1992;15:591–595.

    Article  PubMed  CAS  Google Scholar 

  82. Herrmann H, Kuhl A, Maier-Lenz H. Der Einfluss des Dosierungszeitpunktes von Isosorbidemononitrat auf objektiv und subjektiv Parameter der Angina pectoris. Arzneimittelforschung 1988;38:694–698.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ingela Wiklund
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Diego Ardissino M.D. Lionel H. Opie M.D., Ph.D. Stefano Savonitto M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wiklund, I. (1994). Quality of Life Assessments in Clinical Trials of Angina Pectoris. In: Ardissino, D., Opie, L.H., Savonitto, S. (eds) Drug Evaluation in Angina Pectoris. Developments in Cardiovascular Medicine, vol 158. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2628-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2628-5_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6127-5

  • Online ISBN: 978-1-4615-2628-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation